Sansure Biotech's total inventories for the quarter that ended in Mar. 2026 was ¥443 Mil. Sansure Biotech's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ¥428 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Sansure Biotech's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ¥3.80.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sansure Biotech's Days Inventory for the
three
months ended in Mar. 2026 was 334.92.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sansure Biotech's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sansure Biotech's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.98.
Sansure Biotech (SHSE:688289) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Sansure Biotech's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sansure Biotech's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Sansure Biotech Total Inventories Related Terms
Sansure Biotech Total Inventories Historical Data
* Premium members only.
The historical data trend for Sansure Biotech's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Sansure Biotech (SHSE:688289) has a Total Inventories of ¥443 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Sansure Biotech and its competitors.
Is Sansure Biotech's Total Inventories too high?
Sansure Biotech's current Total Inventories is ¥443 Mil. Overall, Sansure Biotech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Total Inventories compare to ISRG and BDX?
Sansure Biotech's Total Inventories of ¥443 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Sansure Biotech and its competitors. Sansure Biotech's current Total Inventories is ¥443 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.52, compared to a current price of ¥14.40 — trading 29.8% below its estimated fair value. The current Total Inventories is ¥443 Mil. Sansure Biotech's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Total Inventories is ¥443 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sansure Biotech (SHSE:688289) Overvalued in 2026?
Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued.
The current stock price of ¥14.40 is trading 29.8% below its estimated GF Value™ of ¥20.52.
GuruFocus considers Sansure Biotech to be Possible Value Trap.
Key valuation signals for SHSE:688289:
Total Inventories: ¥443 Mil
GF Value™: ¥20.52 vs. price of ¥14.40 (29.8% below fair value)
No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688289 has been successfully added to your 
